Srivastava Akhil, Babu Anish, Filant Justyna, Moxley Katherine M, Ruskin Rachel, Dhanasekaran Danny, Sood Anil K, McMeekin Scott, Ramesh Rajagopal
J Biomed Nanotechnol. 2016 Jun;12(6):1159-73. doi: 10.1166/jbn.2016.2205.
The bottleneck in current vector-based cancer therapy is the targeted and controlled release of therapeutics in tumors. Exosomes are submicron-sized vesicles that are secreted by all cell types and are involved in communication and transportation of materials between cells. Analogous in size and function to synthetic nanoparticles, exosomes offer many advantages, rendering them the most promising candidates for targeted drug or gene delivery vehicles. Patient-specific customized therapeutic strategies can be engineered using exosomes derived from the patient's own healthy cells. Therefore, exosome-based cancer therapy has the potential to become an important part of personalized medicine. Interest in exosomes as carrier organelles is relatively recent. Knowledge about exosomal biology and its applications remains limited. The present review is an attempt to describe the current status of the application of exosomes to cancer therapy and the potential challenges associated with their use.
当前基于载体的癌症治疗的瓶颈在于治疗药物在肿瘤中的靶向和控释。外泌体是由所有细胞类型分泌的亚微米级囊泡,参与细胞间的物质通讯和运输。外泌体在大小和功能上与合成纳米颗粒类似,具有许多优势,使其成为靶向药物或基因递送载体最有前景的候选者。可以使用源自患者自身健康细胞的外泌体设计患者特异性的定制治疗策略。因此,基于外泌体的癌症治疗有潜力成为个性化医疗的重要组成部分。对外泌体作为载体细胞器的兴趣相对较新。关于外泌体生物学及其应用的知识仍然有限。本综述旨在描述外泌体在癌症治疗中的应用现状以及与其使用相关的潜在挑战。